Abstract:IntroductionAvailable data show that approximately 8%–18% of patients with primary hypertension will develop resistant hypertension. In recent years, catheter-based renal denervation (RDN) has emerged as a potential treatment option for resistant hypertension. A number of observational studies and randomised controlled trials among non-Chinese patients have demonstrated its potential safety and efficacy.Methods and analysisThis is a multicentre, randomised, open-label, parallel-group, active controlled trial that will investigate the efficacy and safety of a 5F saline-irrigated radiofrequency ablation (RFA) used for RDN in the treatment of Chinese patients with resistant hypertension. A total of 254 patients who have failed pharmacological therapy will be enrolled. Eligible subjects will be randomised in a 1:1 ratio to undergo RDN using the RFA plus antihypertensive medication or to receive treatment with antihypertensive medication alone. The primary outcome measure is the change in 24 hours average ambulatory systolic blood pressure from baseline to 3 months, comparing the RDN-plus-medication group with the medication-alone group. Important secondary endpoints include the change in office blood pressure from baseline to 6 months after randomisation. Safety endpoints such as changes in renal function will also be evaluated. The full analysis set, according to the intent-to-treat principle, will be established as the primary analysis population.Ethics and disseminationAll participants will provide informed consent; the study protocol has been approved by the Independent Ethics Committee for each site. This study is designed to investigate the efficacy and safety of RDN using a 5F saline microirrigated RFA. Findings will be shared with participating hospitals, policymakers and the academic community to promote the clinical management of resistant hypertension in China.Trial registrationClinicalTrials.gov ID:NCT02900729; pre-results.

Research status and frontiers of renal denervation for hypertension: a bibliometric analysis from 2004 to 2023

Present Evidence of Determinants to Predict the Efficacy of Renal Denervation

Research Progress of Catheter-based Renal Denervation Devices

Renal Denervation in the Antihypertensive Arsenal - Knowns and Known Unknowns.

The role of renal denervation in cardiology and beyond: An updated comprehensive review and future directives

Renal denervation - current evidence and perspectives

Current perspectives and trends of the research on hypertensive nephropathy: a bibliometric analysis from 2000 to 2023

The Evolution of Renal Denervation for the Treatment of Hypertension: Insights from Trials and Prospects for Clinical Practice

Effect of renal denervation on long-term outcomes in patients with resistant hypertension

Clinical Benefits of Renal Denervation Besides Blood Pressure Reduction

Renal Denervation in the Management of Resistant Hypertension: A Comprehensive Review of Literature

Renal denervation for hypertensive heart disease and atrial fibrillation

Renal denervation in the treatment of drug-resistant hypertension: current knowledge and future perspectives

Examining the provision of renal denervation therapy in low- and middle-income nations: Current landscape, challenges, future prospects-A mini perspective review

Renal denervation for hypertension: a case report and literature review

Efficacy and safety of renal denervation for hypertension in patients with chronic kidney disease: a meta-analysis

Efficacy and Safety of Renal Denervation for Chinese Patients with Resistant Hypertension Using a Microirrigated Catheter: Study Design and Protocol for a Prospective Multicentre Randomised Controlled Trial

The Efficacy of Renal Denervation in Treating Resistant Hypertension: A Systematic Review

Advances in Renal Sympathetic Denervation

Percutaneous Renal Denervation in the Management of Hypertension: Chinese Expert Scientific Statement

Opportunities and Limitations of Renal Denervation: Where Do We Stand?